BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Changou CA, Shiah HS, Chen LT, Liu S, Luh F, Liu SH, Cheng YC, Yen Y. A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. Oncologist 2021;26:e367-73. [PMID: 33140457 DOI: 10.1002/onco.13582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Reference Citation Analysis]
2 Cheon C. Synergistic effects of herbal medicines and anticancer drugs: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27918. [PMID: 34797348 DOI: 10.1097/MD.0000000000027918] [Reference Citation Analysis]
3 Li K, Xiao K, Zhu S, Wang Y, Wang W. Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges. Front Pharmacol 2022;13:889799. [DOI: 10.3389/fphar.2022.889799] [Reference Citation Analysis]
4 Cheng CL, Fang WQ, Lin YJ, Yuan CT, Ko BS, Tang JL, Tien HF. Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma. J Cancer Res Clin Oncol 2021. [PMID: 34228224 DOI: 10.1007/s00432-021-03719-y] [Reference Citation Analysis]
5 Brown ZJ, Hewitt DB, Pawlik TM. Experimental drug treatments for hepatocellular carcinoma: Clinical trial failures 2015 to 2021. Expert Opin Investig Drugs 2022. [PMID: 35580650 DOI: 10.1080/13543784.2022.2079491] [Reference Citation Analysis]
6 Wang L, Xu HL, Liang JW, Ding YY, Meng FH. An Integrated Network, RNA Sequencing, and Experiment Pharmacology Approach Reveals the Active Component, Potential Target, and Mechanism of Gelsemium elegans in the Treatment of Colorectal Cancer. Front Oncol 2020;10:616628. [PMID: 33425771 DOI: 10.3389/fonc.2020.616628] [Reference Citation Analysis]
7 Luo XY, Wu KM, He XX. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Exp Clin Cancer Res 2021;40:172. [PMID: 34006331 DOI: 10.1186/s13046-021-01968-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
8 Montella L, Sarno F, Ambrosino A, Facchini S, D'Antò M, Laterza MM, Fasano M, Quarata E, Ranucci RAN, Altucci L, Berretta M, Facchini G. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. Cells 2021;10:1909. [PMID: 34440678 DOI: 10.3390/cells10081909] [Reference Citation Analysis]